Literature DB >> 17034424

Toll-like receptor interactions: tolerance of MyD88-dependent cytokines but enhancement of MyD88-independent interferon-beta production.

Andrea Broad1, John A Kirby, David E J Jones.   

Abstract

Toll-like receptors (TLRs) signal through two main pathways: a myeloid differentiation factor (MyD)88-dependent pathway that acts via nuclear factor kappaB (NF-kappaB) to induce proinflammatory cytokines such as tumour necrosis factor-alpha (TNF-alpha) and a MyD88-independent pathway that acts via type I interferons to increase the expression of interferon-inducible genes. Repeated signalling through TLR4 and a number of other TLRs has been reported to result in a reduction in the subsequent proinflammatory cytokine response, a phenomenon known as TLR tolerance. In this study we have shown that, whilst NF-kappaB activation and production of TNF-alpha and interleukin-12 by murine RAW264.7 and J774.2 cells in response to stimulation by TLR4, -5, -7 or -9, was reduced by prior stimulation with TLR4, -5, -7 or -9 ligands, the primary stimulation of TLR3, which does not use the MyD88 pathway, did not reduce the TNF-alpha or interleukin-12 responses to subsequent TLR stimulation. The response to TLR3 stimulation was not diminished by prior TLR ligand exposure. Furthermore, the production of interferon-beta (IFN-beta) following stimulation of TLR3 or -4, which is MyD88-independent, was increased by prior activation of TLR4, -5, -7 or -9. In contrast, TLR9 ligand-induced IFN-beta production, which is MyD88-dependent, was tolerized by prior TLR stimulation. These results are consistent with differential regulation of MyD88-dependent and MyD88-independent cytokine production following serial activation of TLRs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17034424      PMCID: PMC2265871          DOI: 10.1111/j.1365-2567.2006.02485.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  51 in total

Review 1.  Toll-like receptor signalling.

Authors:  Shizuo Akira; Kiyoshi Takeda
Journal:  Nat Rev Immunol       Date:  2004-07       Impact factor: 53.106

2.  Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation.

Authors:  Nicole Cusson-Hermance; Smriti Khurana; Thomas H Lee; Katherine A Fitzgerald; Michelle A Kelliher
Journal:  J Biol Chem       Date:  2005-08-22       Impact factor: 5.157

Review 3.  Heat shock proteins as endogenous adjuvants in sterile and septic inflammation.

Authors:  Francisco J Quintana; Irun R Cohen
Journal:  J Immunol       Date:  2005-09-01       Impact factor: 5.422

Review 4.  TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway.

Authors:  Paul N Moynagh
Journal:  Trends Immunol       Date:  2005-09       Impact factor: 16.687

5.  Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression.

Authors:  A E Medvedev; K M Kopydlowski; S N Vogel
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

6.  The regulation of the expression of inducible nitric oxide synthase by Src-family tyrosine kinases mediated through MyD88-independent signaling pathways of Toll-like receptor 4.

Authors:  Joo Y Lee; Clifford A Lowell; Danielle G Lemay; Hyung S Youn; Sang H Rhee; Kyung H Sohn; Byeong Jang; Jianping Ye; Jin H Chung; Daniel H Hwang
Journal:  Biochem Pharmacol       Date:  2005-10-15       Impact factor: 5.858

7.  Impaired antigen presentation by human monocytes during endotoxin tolerance.

Authors:  K Wolk; W D Döcke; V von Baehr; H D Volk; R Sabat
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

8.  The MyD88-dependent, but not the MyD88-independent, pathway of TLR4 signaling is important in clearing nontypeable haemophilus influenzae from the mouse lung.

Authors:  Catharina W Wieland; Sandrine Florquin; Nico A Maris; Kasper Hoebe; Bruce Beutler; Kiyoshi Takeda; Shizuo Akira; Tom van der Poll
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

9.  Endotoxin priming improves clearance of Pseudomonas aeruginosa in wild-type and interleukin-10 knockout mice.

Authors:  Tushar K Varma; Megan Durham; Erle D Murphey; Weihua Cui; Zhiyu Huang; Cheng Y Lin; Tracy Toliver-Kinsky; Edward R Sherwood
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

10.  Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity.

Authors:  Xiao-Dong Li; Lijun Sun; Rashu B Seth; Gabriel Pineda; Zhijian J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-21       Impact factor: 11.205

View more
  49 in total

1.  Toll-like receptor 7 preconditioning induces robust neuroprotection against stroke by a novel type I interferon-mediated mechanism.

Authors:  Philberta Y Leung; Susan L Stevens; Amy E B Packard; Nikola S Lessov; Tao Yang; Valerie K Conrad; Noortje N A M van den Dungen; Roger P Simon; Mary P Stenzel-Poore
Journal:  Stroke       Date:  2012-03-08       Impact factor: 7.914

2.  TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor-κB Activation: Single-Nucleotide Polymorphism- and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune Response.

Authors:  Ming-Fen Ho; James N Ingle; Tim Bongartz; Krishna R Kalari; Paul E Goss; Lois E Shepherd; Taisei Mushiroda; Michiaki Kubo; Liewei Wang; Richard M Weinshilboum
Journal:  Mol Pharmacol       Date:  2017-06-14       Impact factor: 4.436

Review 3.  Toll-like receptor signaling in endogenous neuroprotection and stroke.

Authors:  B J Marsh; R L Williams-Karnesky; M P Stenzel-Poore
Journal:  Neuroscience       Date:  2008-08-12       Impact factor: 3.590

4.  Toll-like receptor 2 ligand pretreatment attenuates retinal microglial inflammatory response but enhances phagocytic activity toward Staphylococcus aureus.

Authors:  Travis Kochan; Anuj Singla; Joaquin Tosi; Ashok Kumar
Journal:  Infect Immun       Date:  2012-03-19       Impact factor: 3.441

5.  Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.

Authors:  Mariela A Moreno Ayala; María Florencia Gottardo; María Soledad Gori; Alejandro Javier Nicola Candia; Carla Caruso; Andrea De Laurentiis; Mercedes Imsen; Slobodanka Klein; Elisa Bal de Kier Joffé; Gabriela Salamone; Maria G Castro; Adriana Seilicovich; Marianela Candolfi
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-21       Impact factor: 4.553

Review 6.  Ischaemia-reperfusion injury in liver transplantation--from bench to bedside.

Authors:  Yuan Zhai; Henrik Petrowsky; Johnny C Hong; Ronald W Busuttil; Jerzy W Kupiec-Weglinski
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-12-11       Impact factor: 46.802

7.  Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7.

Authors:  Tomoko Hayashi; Christine S Gray; Michael Chan; Rommel I Tawatao; Lisa Ronacher; Maureen A McGargill; Sandip K Datta; Dennis A Carson; Maripat Corr
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-02       Impact factor: 11.205

Review 8.  Toll-like receptors in neurodegeneration.

Authors:  Eitan Okun; Kathleen J Griffioen; Justin D Lathia; Sung-Chun Tang; Mark P Mattson; Thiruma V Arumugam
Journal:  Brain Res Rev       Date:  2008-09-12

Review 9.  Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases.

Authors:  Brenda J Marsh; Mary P Stenzel-Poore
Journal:  Curr Opin Pharmacol       Date:  2007-11-05       Impact factor: 5.547

10.  IL-10-dependent partial refractoriness to Toll-like receptor stimulation modulates gut mucosal dendritic cell function.

Authors:  Ivan Monteleone; Andrew M Platt; Elin Jaensson; William W Agace; Allan McI Mowat
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.